NO20051404L - Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon - Google Patents

Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon

Info

Publication number
NO20051404L
NO20051404L NO20051404A NO20051404A NO20051404L NO 20051404 L NO20051404 L NO 20051404L NO 20051404 A NO20051404 A NO 20051404A NO 20051404 A NO20051404 A NO 20051404A NO 20051404 L NO20051404 L NO 20051404L
Authority
NO
Norway
Prior art keywords
pyridyl
treating
hcv infection
substituted heterocycles
preventing hcv
Prior art date
Application number
NO20051404A
Other languages
English (en)
Inventor
Rajinder Singh
Dane Goff
John Partridge
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of NO20051404L publication Critical patent/NO20051404L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet pyridylsubstituerte heterocykluser og hydroisomerer derav og farmasøytiske preparater derav som inhiberer replikasjon og/eller proliferasjon av HCV-virus. Det er også beskrevet anvendelse av pyridylheterocyklusene og hydroisomerene derav og/eller farmasøytiske preparater omfattende forbindelsene for å behandle eller forebygge HCV-infeksjon.
NO20051404A 2002-08-23 2005-03-17 Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon NO20051404L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40546702P 2002-08-23 2002-08-23
US41783702P 2002-10-11 2002-10-11
US47137303P 2003-05-15 2003-05-15
US10/646,348 US7157473B2 (en) 2002-08-23 2003-08-22 Pyridyl substituted heterocycles useful for treating or preventing HCV infection
PCT/US2003/026478 WO2004018463A2 (en) 2002-08-23 2003-08-22 Pyridyl substituted heterocycles useful for treating or preventing hcv infection

Publications (1)

Publication Number Publication Date
NO20051404L true NO20051404L (no) 2005-05-10

Family

ID=31950772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051404A NO20051404L (no) 2002-08-23 2005-03-17 Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon

Country Status (15)

Country Link
US (3) US7157473B2 (no)
EP (1) EP1530569A2 (no)
JP (1) JP2006501312A (no)
KR (1) KR20050033653A (no)
AU (1) AU2003262831A1 (no)
BR (1) BR0313755A (no)
CA (1) CA2494164A1 (no)
HR (1) HRP20050168A2 (no)
IL (1) IL166639A0 (no)
MX (1) MXPA05002082A (no)
NO (1) NO20051404L (no)
NZ (1) NZ537980A (no)
PL (1) PL374536A1 (no)
RS (1) RS20050175A (no)
WO (1) WO2004018463A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
PL374536A1 (en) * 2002-08-23 2005-10-31 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
EP1620412A2 (en) * 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
US7220745B2 (en) * 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
KR20060084845A (ko) 2003-07-25 2006-07-25 이데닉스 (케이만) 리미티드 Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
JP2007514763A (ja) * 2003-12-19 2007-06-07 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルス（ｈｃｖ）の感染を処置するための組成物および方法
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
JP2007530582A (ja) * 2004-03-26 2007-11-01 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環抗ウイルス化合物およびその使用
JP2008540425A (ja) * 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
EP2196153B1 (en) * 2005-08-10 2015-07-01 C.R.Bard, Inc. Single-insertion, multiple sample biopsy device
KR100890862B1 (ko) * 2005-11-07 2009-03-27 주식회사 엘지화학 유기 발광 소자 및 이의 제조 방법
CN103463084A (zh) * 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
US8362020B2 (en) * 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112017028125A2 (pt) 2015-06-23 2018-08-28 Kissei Pharmaceutical Co., Ltd. derivado de pirazola ou sal farmaceuticamente aceitável do mesmo
CN116535399B (zh) * 2022-01-25 2024-02-27 中国药科大学 3-羟基-5-(异噁唑-5-基)吡啶甲酰甘氨酸类化合物、制法、药物组合物和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852503A (en) 1953-12-31 1958-09-16 American Cyanamid Co 2, 5-bis (p-aminophenyl) furan azo derivatives
NL242505A (no) 1958-08-20
US3335149A (en) 1963-08-21 1967-08-08 Monsanto Co Thiazole diamines
FR1459375A (fr) 1965-10-20 1966-04-29 Westinghouse Electric Corp Copolymères linéaires oxadiazole-imide
SU508198A3 (ru) 1971-07-22 1976-03-25 Группо Лепетит С.П.А. (Фирма) Способ получени производных 1,2,4-триазола
DE2137719A1 (de) 1971-07-28 1973-02-08 Basf Ag Verfahren zur herstellung von aminobenzonitrilen
US3964896A (en) 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US3853893A (en) 1973-04-02 1974-12-10 Squibb & Sons Inc Anthelmintic 5-(pyridyl)-3-(isothiocyanophenyl) oxadiazoles
DE2721955A1 (de) 1977-05-14 1978-11-23 Basf Ag Azofarbstoffe
DE3623302A1 (de) 1985-11-09 1987-05-14 Bayer Ag Nicotinsaeurederivate
DE4016049A1 (de) 1990-05-18 1991-11-21 Basf Ag 3-isoxazolylbenzylester, ihre herstellung und ihre verwendung
JPH04124178A (ja) 1990-09-12 1992-04-24 Sds Biotech Kk 複素環式化合物および該化合物を含有する除草剤
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4137940A1 (de) 1991-11-18 1993-05-19 Basf Ag 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
JPH07508504A (ja) 1992-03-06 1995-09-21 リーカ　ファーマシュティカルズ　エイ／エス 寄生虫又は細菌による疾患の予防と治療
DE4210502A1 (de) 1992-03-31 1993-10-07 Bayer Ag Verwendung von 3-aminosubstituierten Isoxazolderivaten zur Bekämpfung von Endoparasiten, neue 3-aminosubstituierte Isoxazolderivate und Verfahren zu ihrer Herstellung
WO1994017059A1 (en) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Heterocyclic derivative
DE4408084A1 (de) 1994-03-10 1995-09-14 Hoechst Ag 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5962685A (en) 1994-08-02 1999-10-05 Nippon Soda Co., Ltd. Oxazole derivatives, process for producing the same, and herbicide
CN1151147C (zh) * 1995-02-02 2004-05-26 史密丝克莱恩比彻姆有限公司 作为5-ht受体拮抗剂的吲哚衍生物
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US20020035156A1 (en) 1997-04-18 2002-03-21 Barbara Roniker Combination therapy in the prevention of cardiovascular disorders
AU745797B2 (en) 1997-04-18 2002-03-28 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO1999004390A1 (fr) 1997-07-17 1999-01-28 Sony Corporation Support d'enregistrement magnetique et dispositif d'enregistrement/de reproduction magnetique le comprenant
EP1025857A4 (en) 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
DE19860802A1 (de) 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
EP1180518B1 (en) 1999-04-23 2007-01-17 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
DE10032874A1 (de) 2000-07-06 2002-01-17 Bayer Ag Arzneimittelkombinationen gegen virale Erkrankungen
US7495018B2 (en) * 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
US6608058B2 (en) * 2000-04-17 2003-08-19 Dong Wha Pharm. Ind. Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
US6579880B2 (en) 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20020077491A1 (en) 2000-09-05 2002-06-20 Shipps Gerald W. Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
EP1348706B1 (en) * 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
US20030199521A1 (en) 2001-01-13 2003-10-23 Dykstra Christine C. Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection
DE10148598A1 (de) * 2001-04-19 2002-10-24 Bayer Ag Neue Arylsulfonamide als antivirale Mittel
CN1516695A (zh) * 2001-04-19 2004-07-28 用作抗病毒剂的芳基磺酰胺类化合物
WO2003029210A2 (en) * 2001-10-04 2003-04-10 Merck & Co. Inc. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
PL374536A1 (en) 2002-08-23 2005-10-31 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV

Also Published As

Publication number Publication date
MXPA05002082A (es) 2005-06-08
US7157473B2 (en) 2007-01-02
US20080171871A1 (en) 2008-07-17
WO2004018463A2 (en) 2004-03-04
BR0313755A (pt) 2005-06-21
WO2004018463A3 (en) 2004-05-06
JP2006501312A (ja) 2006-01-12
PL374536A1 (en) 2005-10-31
US7332602B2 (en) 2008-02-19
US20070155966A1 (en) 2007-07-05
US7714137B2 (en) 2010-05-11
IL166639A0 (en) 2006-01-15
NZ537980A (en) 2007-08-31
US20040127497A1 (en) 2004-07-01
KR20050033653A (ko) 2005-04-12
EP1530569A2 (en) 2005-05-18
HRP20050168A2 (en) 2005-10-31
AU2003262831A1 (en) 2004-03-11
RS20050175A (en) 2007-09-21
CA2494164A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
NO20051404L (no) Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
DK0951473T3 (da) Cyclosporinderivat, fremstilling af dette og farmaceutiske præparater indeholdende dette
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
AU2002360592A1 (en) Inhibitors of hepatitis c virus
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
DK1200412T3 (da) Antiproliferative imidazolforbindelser
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
DK0763037T3 (da) [a]-Annellerede pyrrolderivater og deres anvendelse i farmacien
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
SE0101932D0 (sv) Pharmaceutical combinations
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE349448T1 (de) Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen
DE60042401D1 (de) Fab-i inhibitoren
DE60211539D1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
NO20056100L (no) Nitrogeninneholdende heteroarylderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application